Below are the most recent publications written about "Inflammatory Bowel Diseases" by people in Profiles.
-
Thangaiyan R, Shanker A, Ballard BR, M'Koma AE. Structural and epitope characterization of anti-DEFA5 monoclonal antibodies clones 1A8 and 4F5 for inflammatory bowel disease subtype diagnostics. Int J Biol Macromol. 2025 Nov; 330(Pt 3):148024.
-
Baccarella A, Patel T, Conrad MA, Macchi M, Boyer B, Pickering O, Borodyanskaya Y, Gaddipati S, Cohen M, Cubero A, Dawany N, Heimall J, Bunin N, Sullivan KE, Kelsen JR. Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2242-2252.e4.
-
Bernstein CN, Fisk JD, Walld R, Bolton JM, Sareen J, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Graff LA, Marrie RA. Psychiatric Comorbidity Does Not Enhance Prescription Opioid Use in Inflammatory Bowel Disease as It Does in the General Population. Inflamm Bowel Dis. 2025 Feb 10; 31(2):386-393.
-
Thangaiyan R, Sakwe AM, Hawkins AT, Washington MK, Ballard BR, Izban MG, Chirwa SS, Hildreth JEK, Shanker A, Blum DL, M'Koma AE. Functional characterization of novel anti-DEFA5 monoclonal antibody clones 1A8 and 4F5 in inflammatory bowel disease colitis tissues. Inflamm Res. 2025 Jan 30; 74(1):30.
-
Ioannou S, Beecham A, Gomez L, Dauer R, Khakoo N, Pascual L, Quintero M, Lopez J, Leavitt JS, Solis N, Ortega M, Deshpande AR, Kerman DH, Proksell S, Torres EA, Haritunians T, Li D, Abreu MT, McGovern DPB, McCauley JL, Damas OM. Ancestral Diversity in Pharmacogenomics Affects Treatment for Hispanic/Latine Populations With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2025 May; 23(6):1008-1018.e7.
-
Dixit D, Ruiz NC, Shen S, Daneshmand A, Rodriguez VI, Qian S, Neal D, Rampertab SD, Zimmermann EM, Kamel AY. Mucosal Healing Among Black and White Patients With Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2024 Aug 01; 15(8):e00737.
-
Rashid M, Rashid R, Saroya S, Deverapalli M, Brim H, Ashktorab H. Saffron as a Promising Therapy for Inflammatory Bowel Disease. Nutrients. 2024 Jul 20; 16(14).
-
Gravina AG, Panarese I, Trotta MC, D'Amico M, Pellegrino R, Ferraraccio F, Galdiero M, Alfano R, Grieco P, Federico A. Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity? World J Gastroenterol. 2024 Mar 07; 30(9):1132-1142.
-
Lin WC, Tai WC, Chang CH, Tu CH, Feng IC, Shieh MJ, Chung CS, Yen HH, Chou JW, Wong JM, Liu YH, Huang TY, Chuang CH, Tsai TJ, Chiang FF, Lu CY, Hsu WH, Yu FJ, Chao TH, Wu DC, Ho AS, Lin HH, Feng CL, Wu KL, Wong MW, Tung CC, Lin CC, Chen CC, Hu HM, Lu LS, Wang HS, Wu IC, Kuo HY, Wu JF, Yao Shih H, Ni YH, Tang SL, Chen PH, Wei SC. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflamm Bowel Dis. 2023 11 02; 29(11):1730-1740.
-
D?az-Mayor DJ, Soto-Gonz?lez A, Alicea KG, N??ez-Gonz?lez S, Merheb PA, V?zquez K, Torres EA, Romaguera J. Gynecologic Conditions in a Cohort with Inflammatory Bowel Disease: A Descriptive Analysis. P R Health Sci J. 2023 09; 42(3):226-232.